HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Novel Ultrasound Scoring System Provides Accurate COVID-19 Diagnosis and Prognosis in Less Than 10 Minutes

By HospiMedica International staff writers
Posted on 14 Sep 2021
Illustration
Illustration
A new study has found that the Lung Ultrasound Severity Index (LUSI), a novel ultrasound score designed to measure the quality and extent of lung involvement, in relation to COVID-19, can be a useful tool in diagnosing COVID-19 in patients with a high pretest probability to have the disease.

The study by researchers from the University of Ferrara (Ferrara, Italy) also found that among the patients diagnosed with COVID-19 who had a high pretest probability to have the disease, the LUSI could also identify those with worse prognosis diagnosis and in-hospital mortality of patients with respiratory distress admitted for suspected COVID-19.

Lung ultrasound is increasingly employed in clinical practice but a standard approach and data about its accuracy still needed. Lung ultrasound having an acknowledged role in the diagnosis and staging of many lung diseases, has been repeatedly evoked as a potentially useful tool in the context of the current pandemic and has been included in many clinical diagnostic pathways of SARS-CoV-2 pneumonia. However, published studies are generally based on score systems that do not consider the patchy ultrasound appearance of SARS-CoV-2 pneumonia, due to the different patterns displayed in the same area.

To resolve this issue, the researchers built a lung ultrasound model that could semi-quantitatively represent the extent of lung involvement and could include the typical patchy appearance of SARS-CoV-2 pneumonia, reporting clearly all data regarding the technical aspect of the lung ultrasound examination, all data regarding the accuracy of the model, and testing it only in regard to the RT-PCR results, the only universally accepted standard reference for the diagnosis of COVID-19. In their study, the team decided to propose and validate the LUSI, a novel ultrasound score designed to measure the quality and extent of lung involvement, in relation to COVID-19 diagnosis and in-hospital mortality of patients with respiratory distress admitted for suspected COVID-19.

Patients with respiratory distress and suspected COVID-19 consecutively admitted in the emergency medicine unit were enrolled for the study. Lung ultrasound examinations were performed blindly to clinical data. The outcomes were diagnosis of COVID-19 pneumonia and in-hospital mortality. The study involved 159 patients, out of which 66% were males and 63.5% had a final diagnosis of COVID-19. The researchers found that COVID-19 patients had a higher mortality rate (18.8% vs. 6.9%) and LUSI (16.14 [8.71] vs. 10.08 [8.92] as compared to non-COVID-19 ones. This model proved able to distinguish between positive cases from negative ones with an Area Under the Receiver Operating Characteristic (AUROC) equal to 0.72 (95% CI 0.64-0.78) and to predict in-hospital mortality with an AUROC equal to 0.81 (95% CI 0.74-0.86), in the whole population, and an AUROC equal to 0.76 (95% CI 0.66-0.84) in COVID-19 patients. The findings indicate that LUSI can be a useful tool in diagnosing COVID-19 in patients with a high pretest probability to have the disease and - among them - identify those with worse prognosis.

Related Links:
University of Ferrara

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Ultrasound Needle Guidance System
SonoSite L25

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more